Free Trial
Memorial Day Savings! Save $100 on MarketBeat All Access
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Claim Your Discount
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$20.86
-0.7%
$22.72
$12.72
$31.77
$2.63B1.582.10 million shs1.16 million shs
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$57.71
+1.0%
$61.97
$52.52
$109.50
$85.87B0.6217.85 million shs11.74 million shs
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
$62.26
-1.9%
$66.07
$38.51
$85.25
$2.73B0.52765,222 shs259,588 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-0.71%-2.16%-12.17%-17.94%+51.60%
Boston Scientific Corporation stock logo
BSX
Boston Scientific
+1.11%+9.59%-11.14%-22.58%-44.86%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-1.92%-0.35%-1.92%-6.53%+44.15%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$20.86
-0.7%
$22.72
$12.72
$31.77
$2.63B1.582.10 million shs1.16 million shs
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$57.71
+1.0%
$61.97
$52.52
$109.50
$85.87B0.6217.85 million shs11.74 million shs
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
$62.26
-1.9%
$66.07
$38.51
$85.25
$2.73B0.52765,222 shs259,588 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-0.71%-2.16%-12.17%-17.94%+51.60%
Boston Scientific Corporation stock logo
BSX
Boston Scientific
+1.11%+9.59%-11.14%-22.58%-44.86%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-1.92%-0.35%-1.92%-6.53%+44.15%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
2.50
Moderate Buy$34.0062.99% Upside
Boston Scientific Corporation stock logo
BSX
Boston Scientific
2.93
Moderate Buy$92.7160.63% Upside
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
2.78
Moderate Buy$90.6745.63% Upside

Current Analyst Ratings Breakdown

Latest BSX, ARQT, and TARS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2026
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Lower Price TargetOutperform$78.00 ➝ $75.00
5/18/2026
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Reiterated RatingBuy$77.00
5/18/2026
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Lower Price TargetBuy$105.00 ➝ $68.00
5/18/2026
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Reiterated RatingBuy$80.00
5/13/2026
Boston Scientific Corporation stock logo
BSX
Boston Scientific
DowngradeHold (C)Hold (C-)
5/7/2026
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
Reiterated RatingBuy$36.00
5/4/2026
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
Reiterated RatingBuy$88.00
4/29/2026
Boston Scientific Corporation stock logo
BSX
Boston Scientific
DowngradeStrong-BuyHold
4/24/2026
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
Initiated CoverageOutperform$105.00 ➝ $98.00
4/23/2026
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Lower Price TargetOutperform$105.00 ➝ $100.00
4/23/2026
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Set Price Target$90.00
(Data available from 5/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$376.07M6.94N/AN/A$1.52 per share13.72
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$20.61B4.16$4.08 per share14.16$17.57 per share3.28
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
$451.36M5.93N/AN/A$8.11 per share7.68
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-$16.14M-$0.03N/A21.73N/A-0.57%-1.41%-0.59%8/5/2026 (Estimated)
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$2.90B$2.3924.1515.391.0517.29%19.17%10.77%7/29/2026 (Estimated)
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-$66.42M-$1.14N/A21.32N/A-9.02%-14.19%-8.89%8/6/2026 (Estimated)

Latest BSX, ARQT, and TARS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2026Q1 2026
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-$0.02-$0.09-$0.07-$0.09$103.68 million$105.40 million
5/6/2026Q1 2026
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-$0.4003-$0.16+$0.2403-$0.16$149.60 million$162.05 million
4/22/2026Q1 2026
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$0.7930$0.80+$0.0070$0.90$5.19 billion$5.20 billion
2/25/2026Q4 2025
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$0.03$0.13+$0.10$999.00$110.79 million$129.50 million
2/23/2026Q4 2025
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-$0.19-$0.20-$0.01-$0.20$144.56 million$151.67 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
N/AN/AN/AN/AN/A
Boston Scientific Corporation stock logo
BSX
Boston Scientific
N/AN/AN/AN/AN/A
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
0.54
2.68
2.46
Boston Scientific Corporation stock logo
BSX
Boston Scientific
0.42
1.90
1.22
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
0.21
3.74
3.71

Institutional Ownership

CompanyInstitutional Ownership
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
N/A
Boston Scientific Corporation stock logo
BSX
Boston Scientific
89.07%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
90.01%

Insider Ownership

CompanyInsider Ownership
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
9.40%
Boston Scientific Corporation stock logo
BSX
Boston Scientific
0.34%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
9.64%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
150125.08 million113.33 millionOptionable
Boston Scientific Corporation stock logo
BSX
Boston Scientific
59,0001.49 billion1.48 billionOptionable
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
5043.02 million38.88 millionOptionable

Recent News About These Companies

Tarsus Pharmaceuticals Inc Ordinary Shares TARS

New MarketBeat Followers Over Time

Media Sentiment Over Time

Arcutis Biotherapeutics stock logo

Arcutis Biotherapeutics NASDAQ:ARQT

$20.86 -0.15 (-0.71%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$20.80 -0.06 (-0.28%)
As of 05/22/2026 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Boston Scientific stock logo

Boston Scientific NYSE:BSX

$57.71 +0.56 (+0.99%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$57.52 -0.19 (-0.33%)
As of 05/22/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Tarsus Pharmaceuticals stock logo

Tarsus Pharmaceuticals NASDAQ:TARS

$62.26 -1.22 (-1.92%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$62.28 +0.02 (+0.04%)
As of 05/22/2026 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.